Skip to main content
. 2019 May 15;199(10):1257–1266. doi: 10.1164/rccm.201804-0628OC

Figure 3.

Figure 3.

Autoantibodies specific for malignant nodules. (A) The percentage of common antibodies between tumor B-cell extracts (BCE) and normal adjacent lung BCE or malignant nodule plasma and benign nodules (BN) plasma (n = 2/group). (B) The specificity of free autoantibodies isolated from ≥50% tumor BCE (i.e., if none of the 10 BN plasmas had a given autoantibody, the specificity is indicated as 100%). (C) Quantification of fluorescent intensity of top autoantibodies with ≥50% sensitivity and ≥70% specificity (n = 10/group) (mean ± SEM; unpaired Student’s t test; *P < 0.02, **P < 0.0002, and ***P < 0.00001). MN = malignant nodule; NAL = normal adjacent lung.